Profile cover photo
Profile photo
Xeptagen SpA
1 follower -
Targeting unmet needs in personalized oncology
Targeting unmet needs in personalized oncology

1 follower
About
Posts

Post has attachment
Add a comment...

Post has attachment
Add a comment...

Post has attachment
Add a comment...

Post has attachment
New paper on iXip in press!

A multicenter prospective study validated the diagnostic accuracy of iXip in a real clinical setting, and showed that the index can predict prostate cancer with accuracy, and thus reduce the number of prostate biopsies without missing any case of tumour. In addition, the study confirmed that high values of iXip are associated with more aggressive forms of cancer.

http://www.sciencedirect.com/science/article/pii/S2468294216300466
Add a comment...

Post has attachment
iXip, il nostro indice per la probabilità di tumore alla prostata, menzionato in un articolo de Il Giornale.
http://www.ilgiornale.it/news/politica/tumore-prostata-diagnosi-salva-vita-1348641.html
Add a comment...

Post has attachment
Xeptagen is currently at the 89th Congress of the Italian Society of Urology (SIU) in Venice Lido. We have a stand on iXip – our novel diagnostic index to avoid unnecessary prostate biopsies.
In addition, Francavilla and colleagues are presenting a poster on the clinical validation of the index, performed in Parma’s university hospital.
Photo
Add a comment...

Post has attachment
This week Xeptagen is attending the IX National Congress of the Italian Society of Health Technology Assessment (siHTA), organized from 13th to 15th October in Riva del Garda (TN).
We’re presenting a poster on the preliminary economical evaluation of Hepa-IC, our ELISA kit, for the monitoring of patients with cirrhosis.
Photo
Add a comment...

Post has attachment
Add a comment...

Post has attachment
Add a comment...

Post has attachment
Add a comment...
Wait while more posts are being loaded